
Phase 1b trial enrolling to test continuous low-dose lenalidomide
The Gabrail Cancer Center (GCC) in Canton, Ohio is the first site to open in a Phase 1b clinical trial that’s evaluating STAR-LLD, Starton Therapeutics’ investigational continuous delivery of low-dose lenalidomide, in people with multiple myeloma. “I’m thrilled to be the study’s lead investigator and excited about the…